Cerus Corporation (CERS)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Cerus Corporation currently loses $5.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 56 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Cerus Corporation
Cerus Corporation develops and sells blood-safety technologies and related blood products in the medical device field. Listed on the NASDAQ as CERS, the company centers its business on the INTERCEPT Blood System for transfusable blood components and generated $206.1 million in FY2025 revenue.
Today's Snapshot
So far today, CERS is trading 1.5% lower at 2.47, while its sector was flat.
Trading Volume
Below 10d avg (1.0M)
265.9K
vs S&P 500 Today
Underperforming Market
-0.93%
Updated: September 10, 2026 at 16:47 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$2.34 - $2.68Sell
- RSI (14)37.58Neutral
- Stochastic %K (14, 3, 3)3.07Buy
- MACD Level (12, 26)-0.06Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.